Vaccine: HPV9, RV5, UNK, UNK, UNK, UNK, UNK
Symptoms: No adverse event, Product storage error
Clinical narrative: improper storage of product in use; no adverse event; Information has been received from Business Partner/CRO on 18-Feb-2025.  This spontaneous report was received from a/an Other health professional and refers to a(n) patient of unknown age and gender.   The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported.   On an unknown date, the patient started therapy with  unknown dosage.  On an unknown date, the patient started therapy with  unknown dosage. On an unknown date, the patient started therapy with . On an unknown date, the patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant (lot #Y008119, expiration date: 18-Jun-2026), dose number 1,.  On an unknown date, the patient started therapy with Hepatitis A Vaccine, Inactivated (lot #Y008338, expiration date: 26-Nov-2025), dose number 1, 0.5 mL (0.5ml),.  On an unknown date, the patient started therapy with Rotavirus Vaccine, Live, Oral, Pentavalent (Rotateq), (lot #2032354, expiration date: 12-Nov-2025), dose number 1, (2ml),.  On an unknown date, the patient started therapy with Hepatitis A Vaccine, Inactivated (VAQTA (25 U/0.5 ML)), (lot #y008119, expiration date: 18-Jun-2026), dose number 1, (0.5ml),.  On an unknown date, the patient started therapy with Rotavirus Vaccine, Live, Oral, Pentavalent (Rotateq), (lot #Y009341, expiration date: 24-Nov-2025), dose number 1, (2ml),.  On an unknown date, the patient started therapy with Pneumococcal 15-valent Conjugate Vaccine (lot #y010035, expiration date: 17-Feb-2027), dose number 1, 0.5 mL (0.5ml),.  On an unknown date, the patient started therapy with Hepatitis A Vaccine, Inactivated (VAQTA (25 U/0.5 ML)), (lot #y008119, expiration date: 18-Jun-2026), dose number 1, 0.5 mL. The patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant for the treatment of prophylaxis.  The patient started therapy with Hepatitis A Vaccine, Inactivated for the treatment of prophylaxis.  The patient started therapy with Rotavirus Vaccine, Live, Oral, Pentavalent (Rotateq), for the treatment of prophylaxis.  The patient started therapy with Hepatitis A Vaccine, Inactivated (VAQTA (25 U/0.5 ML)), for the treatment of prophylaxis.  The patient started therapy with Rotavirus Vaccine, Live, Oral, Pentavalent (Rotateq), for the treatment of prophylaxis.  The patient started therapy with Pneumococcal 15-valent Conjugate Vaccine for the treatment of prophylaxis.  The patient started therapy with  for the treatment of prophylaxis.  The patient started therapy with Hepatitis A Vaccine, Inactivated (VAQTA (25 U/0.5 ML)), for the treatment of prophylaxis.  The patient started therapy with  for the treatment of prophylaxis.  On an unknown date, the patient experienced no adverse event. On an unknown date, the patient experienced improper storage of product in use.   At the reporting time, the outcome of no adverse event and improper storage of product in use was unknown.   The action taken with Human Papillomavirus 9-valent Vaccine, Recombinant. nHepatitis A Vaccine, Inactivated. nRotavirus Vaccine, Live, Oral, Pentavalent. nHepatitis A Vaccine, Inactivated. nRotavirus Vaccine, Live, Oral, Pentavalent. nPneumococcal 15-valent Conjugate Vaccine and Hepatitis A Vaccine, Inactivated was reported as not applicable.